Tests cannabidiol against placebo for Parkinson disease symptoms

Trial details

Who runs it

Laboratorio Elea Phoenix S.A.

Trial code

NCT06629389

Record updated

5 December 2024

Original description

Parkinson disease (PD) is a chronic, progressive neurodegenerative disorder characterized by clinical motor and non-motor symptoms. Knowing the potential benefits has led to the use of cannabis as an alternative therapy.Read full original descriptionShow less

Randomized, Double-blind, Placebo-controlled, Phase II Clinical Trial to Evaluate Safety and Tolerability of Cannabidiol (Kanbis®) for the Treatment of Parkinson's Disease Symptoms

Parkinson disease (PD) is a chronic, progressive neurodegenerative disorder characterized by clinical motor and non-motor symptoms. Knowing the potential benefits has led to the use of cannabis as an alternative therapy.

Inclusion: Participants between 40 and 80 years old; Participants diagnosed with PD according to Movement Disorder Society Clinical Diagnostic Criteria for Parkinson\'s disease (72), and to the Brain Bank Criteria for Parkinson\'s disease, with mild to moderate disease as measured by the modified Hoehn and Yahr scale. (Both clinical criteria are included since many of the study participants were diagnosed with previous criteria and others with current criteria, both of which are very similar and do not change or raise any doubt about the diagnosis of the disease); Participants who have not changed their anti-Parkinson's drugs (or dose) at least one month prior to study entry; Acceptance by the participant by signing the ICF; Subjects capable of giving consent to participate in the study.

Exclusion: Evidence of dementia, Mini-Mental State Exam score less than 24 or with previous diagnosis by cognitive assessment ; Use of dopamine blockers within 180 days prior to study entry; Use of amphetamine inhibitors, cocaine and MAO-A inhibitors within 90 days prior to study entry; Patients who have received within 90 days prior to study entry the following drugs due to drug interactions: valproic acid, felbamate, niacin (nicotinic acid) at doses ≥2000mg/day or nicotinamide (nicotinic acid amide or nicotinamide) at doses ≥3000mg/day, isoniazid, ketoconazole and/or clobazam; Participants who have had a surgical procedure for PD, either deep brain stimulation or surgery for lesion; Severe psychiatric pathology: severe depression, treatment-refractory psychosis. Evaluation by psychiatrist who confirms the pathology. History of hospitalization in a psychiatric center or mental health center is an exclusion criterion regardless of the time spent since hospitalization or the reason for which the patient was hospitalized; Known or suspected allergy to cannabinoids or inactive ingredients used in the formulation of the study drug; History of drug or alcohol dependence; Moderate-severe liver disease. (Child Pugh B-C); Unstable medical condition detected by the following laboratory alterations: Hemoglobin\<10g/dL, Leukocytes\<4000 u/ml, Neutrophils\<1500 u/ml, Lymphocytes\<500u/ml, Platelets\<100000 u/ml, Aspartate aminotransferase (AST) and alanine aminotransferase (ALT)\> 3 times the upper limit of normal; Women of reproductive age who do not agree to use at least one contraceptive method of proven efficacy (diaphragm or partner using condom, oral or implanted hormonal contraceptive; intrauterine device, stable partner with vasectomy), until at least four weeks after completion of study treatment. Pregnancy blood test will be performed before starting the study; Pregnant or breastfeeding; Patients de novo or with recent diagnosis of PD (less than 5 years).

ClinicalTrials.gov NCT06629389